Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New and unexpected: forkhead meets ARF.

Robert H Costa1, Vladimir V Kalinichenko, Michael L Major

  • 1Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, College of Medicine, Chicago, Illinois 60607, USA. robcosta@uic.edu

Current Opinion in Genetics & Development
|January 22, 2005
PubMed
Summary

Mice lacking the Foxm1b transcription factor resist liver cancer. A p19ARF peptide inhibits Foxm1b, offering a potential therapy for hepatocellular carcinoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergence of fibrotic pericytes and their transcriptional regulation in pulmonary fibrosis.

Nature communications·2026
Same author

FOXM1 inhibitor, RCM‑1, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma.

International journal of oncology·2026
Same author

FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis after neonatal hyperoxic lung injury.

Nature communications·2026
Same author

Rebalancing NTRK2 isoforms promotes vascular regeneration in bronchopulmonary dysplasia.

Cell stem cell·2025
Same author

Impact of carbon nanotubes on pulmonary disorders attributed to occupational and environmental exposures.

Nanomedicine : nanotechnology, biology, and medicine·2025
Same author

Nanoparticle-Based Delivery Systems for Synergistic Therapy in Lung Cancers.

Bioengineering (Basel, Switzerland)·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Hepatocellular carcinoma (HCC) is a lethal cancer.
  • Foxm1b (forkhead box m1b) transcription factor promotes HCC.
  • p19ARF tumor suppressor inhibits Foxm1b early in tumorigenesis, but its expression is lost in advanced tumors.

Purpose of the Study:

  • To investigate the inhibitory mechanism of p19ARF on Foxm1b.
  • To evaluate a p19ARF-derived peptide as a potential HCC therapy.

Main Methods:

  • Structure-function analysis of p19ARF protein domains.
  • Assessment of a modified p19ARF peptide's cellular uptake and inhibitory activity.
  • Evaluation of the peptide's effect on Foxm1b-driven anchorage-independent cell growth.

Related Experiment Videos

Main Results:

  • Amino acids 26-46 of p19ARF bind Foxm1b and inhibit its transcriptional activity by promoting nucleolar targeting.
  • A modified p19ARF peptide (amino acids 24-46) effectively inhibits Foxm1b activity.
  • This peptide prevents Foxm1b-induced anchorage-independent growth, a hallmark of cancer cells.

Conclusions:

  • The p19ARF peptide is a potent inhibitor of Foxm1b transcriptional activity.
  • This p19ARF peptide represents a promising therapeutic strategy for hepatocellular carcinoma by targeting Foxm1b.